OverviewSuggest Edit

Biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor-associated DNA , both in Circulating Tumor Cells and in plasma (cell-free circulating tumor DNA). The Company's mission is to improve outcomes for cancer patients by advancing oncology diagnostics. Biocept utilizes patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. Additionally, the Company offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. Biocept's strategic focus is to promote its unique technology (CEE, cell enrichment and extraction) and family of laboratory tests (OncoCEE) to the Oncology Community. 

The CEE system has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. Examples of these rare cells are circulating tumor cells in patients with early-stage, metastatic or recurrent cancers. Biocept provides products and services to detect and analyze these rare cells in order to provide information that physicians can use to make treatment decisions. The Company employs its unique laboratory tests through an offering of services to medical/surgical oncologists, pathologists, hospitals, cancer centers, universities, and pharmaceutical/clinical researchers.

TypePublic
Founded1993
HQSan Diego, CA, US
Websitebiocept.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Dec 2018)87(-8%)
Job Openings17
Revenue (FY, 2020)$27.5 M(+397%)
Share Price (Jul 2021)$4.2
Cybersecurity ratingCMore

Key People/Management at Biocept

Michael W. Brown

Michael W. Brown

General Counsel, Compliance and Privacy Officer
Michael Terry

Michael Terry

Senior Vice President, Corporate Development
Michael W. Nall

Michael W. Nall

President and Chief Executive Officer, Director
David F. Hale

David F. Hale

Board Member
Marsha A. Chandler

Marsha A. Chandler

Director
M. Faye Wilson

M. Faye Wilson

Lead Independent Director
Show more

Biocept Office Locations

Biocept has an office in San Diego
San Diego, CA, US (HQ)
9955 Mesa Rim Rd
Show all (1)

Biocept Financials and Metrics

Biocept Revenue

Biocept's revenue was reported to be $27.46 m in FY, 2020
USD

Revenue (Q1, 2021)

17.8m

Gross profit (Q1, 2021)

8.8m

Gross profit margin (Q1, 2021), %

49.3%

Net income (Q1, 2021)

2.6m

EBIT (Q1, 2021)

2.7m

Market capitalization (22-Jul-2021)

55.8m

Closing stock price (22-Jul-2021)

4.2

Cash (31-Mar-2021)

14.2m

EV

43.4m
Biocept's current market capitalization is $55.8 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

5.1m3.3m5.5m27.5m

Revenue growth, %

(36%)

Cost of goods sold

6.9m9.3m10.1m11.0m21.3m

Gross profit

(4.3m)(6.8m)(5.4m)6.1m
Quarterly
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

4.6m2.1m3.4m9.3m14.4m

Accounts Receivable

129.0k1.2m1.6m3.5m14.1m

Prepaid Expenses

296.1k2.2m

Inventories

484.6k498.7k587.2k768.0k1.9m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

14.0m10.0m5.9m9.3m2.6m9.0m14.8m12.6m6.5m21.5m24.1m14.2m

Accounts Receivable

834.9k994.7k1.1m1.3m1.4m1.5m1.9m2.2m2.9m3.4m3.2m17.1m

Prepaid Expenses

586.3k497.1k429.1k852.1k697.7k

Inventories

525.5k631.2k775.1k491.0k537.0k581.5k577.3k605.5k687.2k918.7k973.7k3.3m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(18.4m)(21.6m)(24.6m)(25.1m)(17.8m)

Depreciation and Amortization

322.0k575.7k800.9k931.7k1.1m

Inventories

494.7k100.9k(50.0k)(194.9k)(1.4m)

Accounts Payable

332.7k349.9k601.9k14.8k4.5m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(6.4m)(12.5m)(18.6m)(5.9m)(13.7m)(19.4m)(8.3m)(14.8m)2.6m

Depreciation and Amortization

179.8k357.2k580.4k222.1k451.0k691.2k242.8k477.4k366.2k

Inventories

412.9k22.4k30.4k9.7k9.4k(27.1k)(120.2k)(176.0k)(259.9k)(1.3m)

Accounts Payable

1.4m1.8m1.6m204.2k435.7k413.7k152.6k(71.7k)(198.4k)412.9k(4.9k)(332.7k)
USDFY, 2016

Financial Leverage

11.5 x
Show all financial metrics

Biocept Cybersecurity Score

Cybersecurity ratingPremium dataset

C

70/100

SecurityScorecard logo

Biocept Online and Social Media Presence

Embed Graph

Biocept News and Updates

Thinking about buying stock in Biocept, Histogen, Idera Pharmaceuticals, Satsuma Pharmaceuticals, or Clover Health Investments?

NEW YORK, June 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BIOC, HSTO, IDRA, STSA, and CLOV. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Insights on the Liquid Biopsy Global Market to 2028 - Featuring Qiagen NV, Biocept and Illumina Among Others

Dublin, May 26, 2021 (GLOBE NEWSWIRE) -- The "Global Liquid Biopsy Market by Clinical Application, Therapeutic Application, Biomarker Type, Analysis Platform, Analysis Purpose, Product, Industry Verticals, and Geography - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering…

Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Dec. 31, 2020 /PRNewswire/ -- Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, today announced that it has granted...

Thinking about buying stock in Pacific Ethanol, Inovio Pharmaceuticals, Scientific Games, Biocept, or Delta Air Lines?

NEW YORK, Sept. 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PEIX, INO, SGMS, BIOC, and DAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Biocept to Present at the Proactive One2One Virtual Investor Forum on August 25

SAN DIEGO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at t…

Thinking about buying stock in Immatics NV, Biocept Inc, LMP Automotive, Unity Biotechnology, or Barrick Gold Corp?

NEW YORK, Aug. 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IMTX, BIOC, LMPX, UBX, and GOLD. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Biocept Frequently Asked Questions

  • When was Biocept founded?

    Biocept was founded in 1993.

  • Who are Biocept key executives?

    Biocept's key executives are Michael W. Brown, Michael Terry and Michael W. Nall.

  • How many employees does Biocept have?

    Biocept has 87 employees.

  • What is Biocept revenue?

    Latest Biocept annual revenue is $27.5 m.

  • What is Biocept revenue per employee?

    Latest Biocept revenue per employee is $315.6 k.

  • Who are Biocept competitors?

    Competitors of Biocept include Castle Biosciences, Evox Therapeutics and MLL Munich Leukemia Laboratory.

  • Where is Biocept headquarters?

    Biocept headquarters is located at 9955 Mesa Rim Rd, San Diego.

  • Where are Biocept offices?

    Biocept has an office in San Diego.

  • How many offices does Biocept have?

    Biocept has 1 office.